Guiyang Xintian Pharmaceutical Co Ltd Asset Resilience Ratio

Latest as of March 2026: 0.00%

Guiyang Xintian Pharmaceutical Co Ltd asset resilience ratio. Guiyang Xintian Pharmaceutical Co Ltd (002873) has an Asset Resilience Ratio of 0.00% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Guiyang Xintian Pharmaceutical Co Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

CN¥89.77K
≈ $13.14K USD Cash + Short-term Investments

Total Assets

CN¥2.09 Billion
≈ $306.09 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Guiyang Xintian Pharmaceutical Co Ltd (2020–2025)

Asset resilience ratio of Guiyang Xintian Pharmaceutical Co Ltd from 2020 to 2025. This chart shows how Guiyang Xintian Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read Guiyang Xintian Pharmaceutical Co Ltd total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Guiyang Xintian Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Guiyang Xintian Pharmaceutical Co Ltd assets under control.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥89.77K 0.0%
Total Liquid Assets CN¥89.77K 0.00%

Asset Resilience Insights

  • Limited Liquidity: Guiyang Xintian Pharmaceutical Co Ltd maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Guiyang Xintian Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Guiyang Xintian Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Bavarian Nordic
CO:BAVA
Biotechnology 10.83%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 37.31%

Guiyang Xintian Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2020–2025)

Guiyang Xintian Pharmaceutical Co Ltd asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Guiyang Xintian Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.00% CN¥96.87K
≈ $14.18K
CN¥2.12 Billion
≈ $310.38 Million
0.00pp
2024-12-31 0.01% CN¥118.68K
≈ $17.37K
CN¥1.95 Billion
≈ $285.42 Million
+0.00pp
2023-12-31 0.00% CN¥94.33K
≈ $13.80K
CN¥1.91 Billion
≈ $279.76 Million
0.00pp
2022-12-31 0.01% CN¥111.58K
≈ $16.33K
CN¥1.84 Billion
≈ $269.81 Million
-5.24pp
2021-12-31 5.25% CN¥80.00 Million
≈ $11.71 Million
CN¥1.52 Billion
≈ $223.07 Million
-2.43pp
2020-12-31 7.68% CN¥118.00 Million
≈ $17.27 Million
CN¥1.54 Billion
≈ $224.76 Million
--
pp = percentage points

About Guiyang Xintian Pharmaceutical Co Ltd

SHE:002873 China Biotechnology
Market Cap
$268.97 Million
CN¥1.84 Billion CNY
Market Cap Rank
#15094 Global
#4435 in China
Share Price
CN¥7.53
Change (1 day)
+1.07%
52-Week Range
CN¥7.16 - CN¥11.90
All Time High
CN¥103738.98
About

Guiyang Xintian Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of new traditional Chinese medicines in China. The company offers products in various dosage forms, including hard capsules, oral solutions, granules, gels, tablets, syrups, tinctures, lotions, medicated wines, and elixirs. Its products are used for the treatment of … Read more